The purpose of this study is to learn more about three kidney diseases called nephrotic syndrome: Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN). By collecting health information and laboratory samples from individuals who have these diseases and by making this information available to researchers, we hope to gain new knowledge about these diseases and to find better treatments for them.

The rationale for this study is to determine if there is a difference in symptoms or complications among patients undergoing uncomplicated ureteroscopy for stone removal with shorter indwelling stent duration. Curently there are only a few small studies exploring the optimal duration of stent placement after stent placement and no multicenter randomized control trials.

We have created this registry to provide an opportunity to study diagnostic capabilities, administration protocols and long-term effects of contrast-enhanced ultrasound (CEUS) of any organ.

Study to evaluate the safety and effectiveness of the InnAVasc Arteriovenous Graft (IG) for hemodialysis (HD) access in patients with end-stage renal disease (ESRD).

We are collecting data on children living with chronic kidney disease, including children on dialysis or with a kidney transplant, to learn more about what happens over time. The data collected will be used for research projects.

Current dialysis vascular access patient education materials can be overwhelming, not written in plain language, and not have enough realistic information about the steps involved in getting a dialysis vascular access before starting hemodialysis. This study is being done to create and test a dialysis vascular access educational video for patients. Participants would take part in a one-time interview about their thoughts on dialysis vascular access education and their ideas for a vascular access video.

To compare disease-free survival (DFS) as assessed by the investigator for high-risk renal cell carcinoma patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone.

The purpose of this IRB approved Humanitarian Use of a device is to allow patients to be treated with LDL-Apheresis, using the LIPOSORBER® LA-15 system. This device is approved for adult and pediatric patients with Focal Segmental Glomeruloslerosis as a Humanitarian Use Device. Its effectiveness has not been demonstrated.

This study will collect information about children who have rare types of lung disease to help us understand how better to diagnose and treat these patients. Information will be collected from participants' doctors about how different aspects of their disease and treatment. This will be compared to information from other such patients from other hospitals around the United States. By gathering information on many such patients, we hope to develop best practices for such patients. These may lead to new research studies, which we can invite participants in this study to consider as well.

To test the effect of automated RBC exchange transfusion and standard of care compared with standard of care on the number of episodes of clinical worsening of sickle cell disease (SCD)requiring acute health care encounters (non-elective infusion center/ER/Hospital visits) or resulting in death over 12 months in high risk adult SCD patients.